Stem Cell Clinic

Pacira BioSciences Receives FDA 510k Clearance for New iovera° SmartTip to Manage Chronic Low Back Pain via Long-lasting Medial Branch Nerve Block

By Platelet Rich Plasma Injections

PARSIPPANY, N.J., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, announced today that it has received clearance from the U.S. Food & Drug Administration (FDA) to market a new Smart Tip designed to access the medial branch nerves to manage chronic low back pain.

Excerpt from:
Pacira BioSciences Receives FDA 510k Clearance for New iovera° SmartTip to Manage Chronic Low Back Pain via Long-lasting Medial Branch Nerve Block

QUANTRO Therapeutics achieves breakthrough in transcriptomic drug discovery with first successful simultaneous 10-target multiplex-screening

By Platelet Rich Plasma Injections

VIENNA, Austria, Jan. 07, 2025 (GLOBE NEWSWIRE) -- QUANTRO Therapeutics (QUANTRO), a pioneer in the discovery of first-in-class transcription factor targeting cancer treatments, announced today that the company has successfully completed its first ten-target multiplex-screening campaign, which yielded validated hits and functional proof of on-target activity for multiple molecular targets. This milestone further expands the capability to establish QUANTRO’s innovative QUANTROseq® platform as a pioneering technology in the fight against diseases driven by transcriptional dysregulation, such as cancer and inflammation indications.

Read more:
QUANTRO Therapeutics achieves breakthrough in transcriptomic drug discovery with first successful simultaneous 10-target multiplex-screening

Achieve Life Sciences Announces Critical Milestone Successfully Reached in ORCA-OL Cytisinicline Clinical Trial Required for NDA Submission

By Platelet Rich Plasma Injections

Over 300 Participants Have Completed Cumulative Six Months of Cytisinicline Treatment in the ORCA-OL Trial, Completing the Long-Term Exposure Requirement for NDA Submission

Read more here:
Achieve Life Sciences Announces Critical Milestone Successfully Reached in ORCA-OL Cytisinicline Clinical Trial Required for NDA Submission

Sutro Biopharma and Boehringer Ingelheim BioXcellence™ collaboration: Established first-in-class cell-free capabilities at commercial scale

By Platelet Rich Plasma Injections

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Boehringer Ingelheim BioXcellence™ and Sutro Biopharma Inc. today announced that they successfully applied Sutro’s proprietary cell-free expression technology on a commercial scale to manufacture luveltamab tazevibulin (luvelta), Sutro’s Tubulin FR?-targeting antibody-drug conjugate (ADC) designed to treat a broad range of patients with ovarian cancer and other FR? expressing cancers.

More here:
Sutro Biopharma and Boehringer Ingelheim BioXcellence™ collaboration: Established first-in-class cell-free capabilities at commercial scale

Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study

By Platelet Rich Plasma Injections

REDWOOD CITY, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to improve the lives of patients with diabetes, obesity, and genetically defined cancers, today announce compelling results from in vivo studies of icovamenib in combination with semaglutide.

See the original post here:
Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study

Bioxytran Announces Government Interest After Initial BARDA Techwatch Light Meeting

By Platelet Rich Plasma Injections

BOSTON, MASSACHUSETTS, Jan. 07, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, fibrosis, stroke, dementia, and Alzheimer's disease, announced a well-attended Techwatch Light meeting hosted by the Biomedical Advanced Research and Development Authority (BARDA) to introduce the company to the government, and help facilitate and direct the Company’s approach toward finding programs within the government capable of funding its development initiatives.

Read more:
Bioxytran Announces Government Interest After Initial BARDA Techwatch Light Meeting

Cyclarity Therapeutics Secures Approval for First-in-Human Clinical Trial

By Platelet Rich Plasma Injections

NOVATO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Cyclarity Therapeutics is pleased to announce regulatory approval to begin its first-in-human clinical trial. The trial will be conducted at CMAX, one of Australia’s leading clinical research centers, in partnership with Monash University. This effort will be led by Dr. Stephen Nicholls of the Victorian Heart Institute (VHI), a distinguished leader in cardiovascular medicine. In addition to a traditional SAD/MAD phase 1 trial, the authorization includes an allowance to enroll 12 patients with Acute Coronary Syndrome (ACS) to assess the safety of UDP-003 in individuals with plaque buildup, as well as to explore anecdotal evidence of efficacy. This represents a critical first step in evaluating the potential impact of our therapy in a population with high unmet need.

Read the original post:
Cyclarity Therapeutics Secures Approval for First-in-Human Clinical Trial

Shuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

By Platelet Rich Plasma Injections

GAITHERSBURG, Md., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced that CEO, Anatoly Dritschilo, M.D., will participate in a webcasted fireside chat at the Lytham Partners 2025 Investor Healthcare Summit, taking place virtually on Monday, January 13, 2025.

Continue reading here:
Shuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

→←